2F50 Stock Chart & Stats
€2.26
>-€0.01(-0.94%)
At close: 4:00 PM EDT
€2.26
>-€0.01(-0.94%)
Day’s Range― - ―
52-Week Range€1.82 - €12.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€625.63K
Enterprise Value€7.79M
Total Cash (Recent Filing)€2.85M
Total Debt (Recent Filing)€3.58M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-62161.60
Shares Outstanding706,586
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contracted CDMO GrowthThe $5.1M contracted engagement materially improves revenue visibility beyond the current quarter and extends activity into 2027. Advance and milestone payments can support working capital, while the program should increase utilization and deepen Scinai’s position in outsourced development and clinical manufacturing.
Expanded Commercial CapabilitiesThe acquired Yavne operations broaden Scinai’s service offering and complement its Jerusalem capabilities across biologics, analytical work, aseptic processing, and clinical manufacturing. This integrated platform can support larger customer programs and create a more durable foundation for repeat CDMO relationships.
Improved Capital StructurePositive equity and moderate leverage provide a stronger financial base than the negative-equity periods in 2022–2023. Although losses remain significant, debt below equity gives Scinai more flexibility to pursue commercial execution and manage its expanded operations than a highly leveraged structure would.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow means current activities do not fund themselves internally. Scinai must convert contracts into cash, improve utilization, or raise capital to sustain operations, making liquidity management a continuing constraint on R&D and CDMO expansion.
Severe Operating LossesThe enlarged two-site cost base currently exceeds the revenue generated by the business, producing substantial gross and operating losses. Until utilization rises and contracted work is recognized, Scinai’s commercial growth may not translate into durable margins or reduced funding dependence.
Dilution From FinancingExternal financing is important while cash burn persists, but the proposed securities and warrant transactions can dilute existing holders. Continued use of the SEPA could expand the share base further, reducing the benefit of future operating improvements accruing to current shareholders.
Scinai Immunotherapeutics News
2F50 FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was €1.82 and its highest was €12.70 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is €625.63K.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Dec 02, 2026 which is in 48 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Aug 20, 2026. The company reported -€3.268 earnings per share for the quarter.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 706,586 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -€3.268 in its last earnings report. Following the earnings report the stock price went up 15.365%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in DE:2F50
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
GT Biopharma
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―